QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Hisense, a leading global home appliance and consumer electronics brand, has reinforced its competitive strength in the global market. Hisense's global TV shipments reached 29.14 million units in 2024, accounting for 14% of the global market share, according to data from the international market research institute Omdia. Hisense has secured the No. 2 position globally from 2022 through 2024, stands as the only TV manufacturer to achieve continuous growth over seven consecutive years.
Hisense has solidified its position as the global leader in the large-screen TV market. With a 19.8% market share in shipments for TVs sized 75 inches and above, Hisense ranks first globally. In the ultra-large TV segment, Hisense holds a dominant market share of 30.3% for 98-inch+ models and an impressive 58.8% for 100-inch+ models, also securing the top global position. According to GFK and Circana, Hisense TVs rank first in countries such as Japan, Australia, South Africa, and Slovenia.
Hisense's ongoing success in a highly competitive market is due to its commitment to user-centric technology and ultimate quality, enhancing everyday life for customers. As the pinnacle of Hisense's technology, the 116-inch TriChroma LED TV features advanced RGB Local Dimming Display Technology. Powered by the Hi-View AI Engine X, it uses AI-driven features like AI Peak Brightness and AI RGB Local Dimming to ensure real-time adjustments for vivid, lifelike visuals. For Hisense, AI is the driving force behind innovation, enhancing viewing experiences and energy efficiency.
Hisense's unwavering commitment to innovation and customer satisfaction has solidified its position as a global TV market leader. By leveraging cutting-edge technology and strategic partnerships, Hisense continues to enhance the viewing experience and set industry standards. As it looks to the future, Hisense is well-positioned to sustain its growth and remain a top choice for consumers worldwide.
About Hisense
Hisense is a leading global home appliance and consumer electronics brand. According to Omdia, Hisense has ranked No. 2 globally in total TV shipments from 2022 to 2024, and No. 1 in 100''+ TVs segment from 2023 to 2024. The company has rapidly expanded to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hisense TV Retains Global No.2 Ranking in 2024 and Leads the 100-Inch TV Market Worldwide
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
